News | March 20, 2024
AstraZeneca buys biopharmaceutical company Fusion
To accelerate the development of next-generation radioconjugates to treat cancer
To accelerate the development of next-generation radioconjugates to treat cancer
Sen spent a decade with Biocon and held various key roles,
Acquisition of exclusive commercialization rights for European markets
Highlighting fully integrated organization, robust portfolio, and strategic priorities to drive long-term sustainable growth
MASH is a chronic and progressive liver disease characterised by fat accumulation and inflammation in the liver,
Pelabresib recently met its primary endpoint of spleen volume reduction and demonstrated favorable trends in symptom improvement
This Phase III clinical trial is a randomized, double-blind, placebo-controlled, multicenter clinical trial in China to evaluate the safety and efficacy of ASC40
This alliance brings together drug innovation capabilities of Glenmark and Ichnos to develop cutting-edge therapies for the treatment of hematological malignancies and solid tumors
The R&D centre is mainly dedicated to the Process R&D of New Chemical Entities (NCE) development projects
This agreement includes upfront and milestone payments with a combined potential value of over $500m and sales royalties.
Subscribe To Our Newsletter & Stay Updated
